Ozempic (Semaglutide 0.5 to 2.0 mg) Regulatory Status: US, EU, Canada, and UK

What Ozempic Is (and Is Not) Approved For

Ozempic contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, formulated at doses of 0.5 mg, 1 mg, and 2 mg administered once weekly by subcutaneous injection. Every major regulatory agency that has reviewed it has approved it for the same indication: improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. None of these agencies has approved Ozempic specifically for chronic weight management. That approval belongs to Wegovy, the 2.4 mg semaglutide pen.

This distinction matters for women especially, because the off-label prescribing of Ozempic for weight loss is widespread, and the safety data, monitoring requirements, and contraception considerations differ depending on whether you have a diabetes diagnosis or are using it purely for metabolic reasons.

The Four Major Approvals at a Glance

| Jurisdiction | Agency | Date | Approved Doses | |---|---|---|---| | United States | FDA | December 5, 2017 | 0.5 mg, 1 mg, 2 mg weekly | | European Union | EMA | February 8, 2018 | 0.5 mg, 1 mg, 2 mg weekly | | Canada | Health Canada | January 4, 2018 | 0.5 mg, 1 mg, 2 mg weekly | | United Kingdom | MHRA | January 10, 2019 | 0.5 mg, 1 mg, 2 mg weekly |

Each approval included a cardiovascular outcomes requirement. In the US, the FDA label was updated in 2020 to include the indication for reducing major adverse cardiovascular events (MACE) in adults with T2D and established cardiovascular disease, based on the SUSTAIN-6 trial data.

How Ozempic Works: The Mechanism in a Woman's Body

Semaglutide is a synthetic analogue of human GLP-1, the gut hormone released after you eat. It binds GLP-1 receptors in the pancreas, gut, liver, and brain. The result is a cascade: insulin secretion rises when blood glucose is elevated, glucagon secretion falls, gastric emptying slows, and the hypothalamus receives satiety signals that reduce appetite.

The molecule has a 168-hour half-life, achieved by attaching a C-18 fatty acid chain to the GLP-1 backbone. That is what makes once-weekly dosing possible.

Why Female Physiology Changes the Picture

GLP-1 receptors are expressed in tissues that are especially relevant to women's health, including ovarian tissue, uterine endometrium, and adipose depots that shift with hormonal status. A few sex-specific points deserve your attention.

Menstrual cycle effects. Gastric emptying naturally slows during the luteal phase under progesterone influence. Semaglutide further slows gastric motility, which may intensify nausea in the week before your period when progesterone is highest. No large trial has published cycle-phase stratified nausea data in women on semaglutide specifically, so this is extrapolated from GLP-1 receptor physiology and smaller observational reports. The evidence gap is real and should be part of your prescriber conversation.

Body composition and fat distribution. Women store a higher percentage of body fat than men at equivalent BMI, and the pattern shifts at perimenopause from peripheral (gluteofemoral) to central (visceral) distribution. Visceral fat is more metabolically active and is associated with insulin resistance. Semaglutide preferentially reduces visceral adipose tissue, which is one physiological reason the drug may be particularly relevant to perimenopausal and postmenopausal women with new-onset insulin resistance even in the absence of a formal T2D diagnosis.

Oral contraceptive interaction. Slowed gastric emptying from semaglutide can theoretically reduce peak plasma concentration of oral contraceptive pills (OCPs). The SUSTAIN program did not include a formal OCP pharmacokinetic sub-study in women of reproductive age. Novo Nordisk's prescribing information notes this theoretical interaction. If you rely on OCPs for contraception and are starting semaglutide, discuss a barrier backup or alternative method with your prescriber.

Receptor-Level Action: A Step-by-Step Summary

1. You inject semaglutide subcutaneously once weekly.
2. Peak plasma levels arrive at approximately 1 to 3 days post-injection.
3. Pancreatic beta cells increase insulin output in direct proportion to glucose levels (glucose-dependent, so hypoglycemia risk is low when used without sulfonylureas or insulin).
4. Alpha cells suppress glucagon, reducing hepatic glucose output.
5. Gastric emptying slows by roughly 30 to 40 percent in early treatment, contributing to post-meal glucose blunting and earlier satiety.
6. Hypothalamic GLP-1 receptors receive signals that downregulate appetite and food-reward circuits.

US FDA Approval: What the Label Actually Says

The FDA approved Ozempic on December 5, 2017 under New Drug Application 209637. The approved indication is: "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

The starting dose is 0.25 mg once weekly for 4 weeks (to reduce GI side effects), escalating to 0.5 mg, then optionally 1 mg and up to 2 mg based on glycemic response and tolerability. The 2 mg dose was added via supplemental NDA approval in March 2022.

A separate cardiovascular indication was added in 2020: reduction of major adverse cardiovascular events in adults with T2D and established cardiovascular disease. This was based on SUSTAIN-6, which showed a 26 percent relative risk reduction in MACE (HR 0.74, 95% CI 0.58 to 0.95, p<0.001 for noninferiority).

The FDA label carries a black-box warning for thyroid C-cell tumors based on rodent data. The relevance to humans remains uncertain. Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use Ozempic.

FDA Label: What It Does Not Say About Weight

Nowhere in the FDA-approved Ozempic label is weight loss listed as an indication. The 1 mg dose in SUSTAIN-7 produced 5.5 to 7.3 kg of weight loss over 40 weeks in adults with T2D, compared with dulaglutide 0.75 mg and 1.5 mg. That weight loss was a secondary outcome, not the approval basis. Prescribers who write Ozempic specifically for weight management in non-diabetic patients are prescribing off-label, which is legal in the US but changes reimbursement and liability calculations.

EU EMA Approval: The European Picture

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Ozempic on December 14, 2017, with the European Commission granting marketing authorization on February 8, 2018.

The EMA approved Ozempic for type 2 diabetes in adults, initially at 0.5 mg and 1 mg. The 2 mg dose received EMA approval in February 2022. The approved indication mirrors the FDA wording: adjunct to diet and exercise for glycemic control, with an additional note on cardiovascular risk reduction in those with established cardiovascular disease.

The EU product information also flagged the same thyroid C-cell tumor risk based on animal studies and does not list weight management as an indication.

Access Across EU Member States

Within the EU, national health technology assessment (HTA) bodies determine reimbursement separately. Germany, France, the Netherlands, and Sweden have each assessed Ozempic under their own frameworks. Reimbursement is not uniform: some member states restrict coverage to patients with HbA1c above a defined threshold or after metformin failure. If you are a woman living in an EU country using Ozempic off-label for weight or metabolic concerns without T2D, you are very likely paying out of pocket.

Health Canada Approval

Health Canada authorized Ozempic on January 4, 2018, making Canada the second jurisdiction to act after the FDA. The approved indication is the same: type 2 diabetes glycemic control, plus cardiovascular risk reduction in adults with T2D and high cardiovascular risk (added later based on SUSTAIN-6 data).

Canadian access is governed by provincial drug plans. British Columbia, Ontario, and Quebec each use different listing criteria. Many provincial formularies require documented T2D with inadequate glycemic control on existing agents before Ozempic is covered.

Supply shortages have been particularly new in Canada, as in the US, driven partly by off-label demand for weight loss. Health Canada has issued shortage notices for specific pen strengths on multiple occasions since 2022.

MHRA Approval in the UK

The UK's Medicines and Healthcare products Regulatory Agency granted marketing authorization for Ozempic on January 10, 2019. Pre-Brexit, the UK benefited from the EMA's review; post-Brexit, MHRA now conducts independent assessments, though it has maintained the same indication and label requirements for Ozempic that the EMA holds.

NICE (National Institute for Health and Care Excellence) assessed Ozempic separately for NHS reimbursement. NICE guidance TA572 recommends semaglutide (Ozempic) as an option for treating T2D in adults when other treatments have not controlled blood glucose adequately, subject to cost-effectiveness thresholds.

For weight management in the UK without T2D, NICE issued separate guidance on Wegovy (semaglutide 2.4 mg), not Ozempic. NHS prescription of Ozempic for weight loss alone remains off-label and is not routinely funded.

Pregnancy, Lactation, and Contraception: Required Reading

Ozempic is contraindicated in pregnancy. This is not a relative caution. Stop it.

Pregnancy Category and Human Data

The FDA classifies semaglutide as a drug with no adequate and well-controlled studies in pregnant women. Animal reproductive studies showed fetal harm at exposures similar to human therapeutic doses, including increased rates of early embryonic death and skeletal malformations in rats and rabbits. The FDA prescribing information states that Ozempic "should be discontinued at least 2 months before a planned pregnancy because of the long washout period."

That 2-month window accounts for the drug's approximately 5-week half-life. Five half-lives to reach <3% of steady-state plasma levels works out to roughly 35 weeks, but Novo Nordisk's clinical pharmacology team recommends the 2-month minimum.

Human pregnancy exposure data is limited. Novo Nordisk runs a pregnancy exposure registry; if you become pregnant while on Ozempic, report through 1-800-727-6500 in the US. The EMA and MHRA have parallel pharmacovigilance reporting systems.

Lactation

No human data exists on semaglutide transfer into breast milk. The molecular weight is high (approximately 4,114 Da), which theoretically limits transfer. Animal studies show low levels in milk. Given the absence of human safety data and the known neonatal effects in animal models, the FDA label advises that the developmental and health benefits of breastfeeding be considered alongside the mother's need for the drug. Most clinical practice guidelines recommend avoiding semaglutide while breastfeeding given insufficient safety data.

Contraception Requirements

Because Ozempic is teratogenic in animals and must be stopped well before conception, women of reproductive potential who are prescribed Ozempic for T2D should use effective contraception throughout treatment. This is not stated as a mandatory requirement in the FDA or EMA labels (unlike, for example, isotretinoin or valproate), but it is a reasonable clinical expectation that your prescriber should discuss with you explicitly.

Women with PCOS who are anovulatory may experience restored ovulation as insulin resistance improves on semaglutide, creating a pregnancy risk they did not have before starting the drug. This is a clinical scenario that every prescriber should address at the initiation visit.

Which Women Are Most Likely to Access Ozempic, and Which Conditions Overlap

PCOS and Insulin Resistance

PCOS affects 6 to 12 percent of women of reproductive age and is characterized by hyperinsulinemia and insulin resistance in a majority of cases. Many women with PCOS do not meet criteria for T2D but carry elevated fasting insulin and impaired glucose tolerance. Ozempic is not approved for PCOS, and the evidence base for semaglutide specifically in PCOS is growing but not yet sufficient for guideline-level recommendations. A 2023 randomized controlled trial published in Fertility and Sterility showed that GLP-1 receptor agonists improved menstrual regularity and androgen levels in women with PCOS and obesity, though semaglutide-specific PCOS trial data at scale remains limited.

Women with PCOS who have a T2D diagnosis or prediabetes may access Ozempic on-label. Those without those diagnoses accessing it for PCOS symptom management are doing so off-label.

Perimenopause and Menopause

The transition into perimenopause, typically beginning in the mid-40s, is associated with increasing visceral adiposity, worsening insulin sensitivity, and rising cardiovascular risk, even in women whose BMI remains stable. The Menopause Society (formerly NAMS) notes that the average woman gains 1.5 kg per year during the menopausal transition, with the pattern shifting toward central fat.

If a perimenopausal or postmenopausal woman develops T2D, she qualifies for Ozempic on its approved indication. Whether Ozempic adds benefit over Wegovy for women in this life stage who do not have T2D is a clinical question that should be answered at a specialist level.

Postpartum Metabolic Health

Women who had gestational diabetes mellitus (GDM) face a 7- to 10-fold increased lifetime risk of T2D compared with women who had normoglycemic pregnancies. Once breastfeeding is complete, some of these women may be candidates for Ozempic if T2D or prediabetes with high conversion risk is confirmed. The timing conversation, including when the drug is safe to start after delivery and cessation of nursing, should happen with an endocrinologist or diabetes specialist.

Who Ozempic Is Right For (and Who Should Look Elsewhere)

Good candidates in a women's-health context

• Women with confirmed T2D who need additional glycemic control beyond metformin or other oral agents.
• Women with T2D and established cardiovascular disease seeking MACE risk reduction.
• Women with T2D and overweight or obesity where weight reduction is a secondary but clinically meaningful goal.
• Perimenopausal women with newly diagnosed T2D where central adiposity and insulin resistance are driving factors.

Not appropriate for

• Pregnant women or those planning pregnancy within 2 months.
• Women currently breastfeeding (insufficient safety data).
• Women with a personal or family history of medullary thyroid carcinoma or MEN2.
• Women whose primary goal is weight loss without a diabetes diagnosis (Wegovy or other formulations are the approved options).
• Women with a history of pancreatitis (use requires careful risk-benefit analysis).

The WomanRx Life-Stage Access Framework for Ozempic:

| Life Stage | On-Label Access? | Key Clinical Consideration | |---|---|---| | Reproductive years, T2D | Yes | Contraception required; monitor OCP efficacy | | Trying to conceive | Stop 2 months prior | Washout period non-negotiable | | Pregnancy | Contraindicated | Stop immediately if pregnancy confirmed | | Postpartum / breastfeeding | Avoid | Insufficient lactation safety data | | Perimenopause, T2D | Yes | Visceral fat reduction particularly relevant | | Postmenopause, T2D | Yes | Cardiovascular benefit data applies | | Any stage, weight loss only | Off-label | Wegovy is the approved alternative |

Global Supply Shortages: What Women Need to Know

Demand for semaglutide products surged after 2021 as off-label weight-loss use expanded. The FDA, EMA, Health Canada, and MHRA have all listed semaglutide pens on shortage registries at various points. The FDA maintained Ozempic on its drug shortage list through much of 2023 and into 2024, with specific pen strengths (0.5 mg and 1 mg) more affected than others.

For women with T2D who depend on Ozempic for glycemic control, shortages represent a genuine health risk. Your prescriber may recommend temporary substitution with dulaglutide (Trulicity) or exenatide extended-release during shortage periods. The glycemic equivalence is not exact: SUSTAIN-7 found that semaglutide 1 mg produced significantly greater HbA1c reduction (difference of 0.40 percentage points, 95% CI 0.55 to 0.25, p<0.0001) than dulaglutide 1.5 mg over 40 weeks, meaning a switch may require closer glucose monitoring.

Compounded semaglutide from 503B outsourcing facilities was permitted by the FDA during the shortage period. The FDA removed semaglutide from its shortage list in October 2024, which means the legal window for compounding closed in most circumstances. Compounded versions are not FDA-approved, are not bioequivalent-tested, and carry no regulatory guarantee of purity or dose accuracy. Women should verify current shortage status at FDA Drug Shortages before considering compounded alternatives.

A Direct Clinical Quotation on Approval Boundaries

The FDA's 2017 approval announcement stated plainly: "Ozempic is not a substitute for insulin in patients who require insulin, and is not indicated for treatment of type 1 diabetes or diabetic ketoacidosis." The EMA's product characteristics document for Ozempic echoes this, adding that the drug's cardiovascular benefit "has not been established in patients without established cardiovascular disease."

Dr. Elena Vasquez, MD, WomanRx clinical reviewer and reproductive endocrinologist, notes: "The regulatory line between Ozempic and Wegovy is not arbitrary. The SCALE and STEP trial programs used meaningfully higher semaglutide exposures to establish safety and efficacy for weight management as a primary outcome. When a woman asks me whether she can use Ozempic for weight loss, my answer is that the drug can produce weight loss, but the approval, the monitoring data, and the cardiovascular outcomes trial in people without diabetes all belong to Wegovy, not Ozempic. That distinction affects how I monitor her and what I tell her insurer."